-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.5

Benzinga·06/06/2025 10:40:29
Listen to the news
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7.25 to $7.5.